Aripiprazole: A review of its use in the treatment of manic episodes in adolescents with bipolar i disorder

CNS Drugs

Volumn 28, Issue 2, 2014, Pages 171-183

  McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CREATINE KINASE; FLUOXETINE; KETOCONAZOLE; LITHIUM; PLACEBO; PROLACTIN; VALPROIC ACID; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT DISEASE; AGGRESSION; AKATHISIA; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BINDING AFFINITY; BIPOLAR I DISORDER; BIPOLAR MANIA; COGNITIVE DEFECT; COMORBIDITY; CREATINE KINASE BLOOD LEVEL; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; IN VITRO STUDY; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; METABOLIC PARAMETERS; MIXED MANIA AND DEPRESSION; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROTRANSMISSION; NOSE OBSTRUCTION; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOMNOLENCE; STEADY STATE; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; YOUNG MANIA RATING SCALE; ADOLESCENT; BIPOLAR DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; EUROPEAN UNION; MEDICATION COMPLIANCE; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPEAN UNION; HUMANS; MEDICATION ADHERENCE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84896811883     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0134-2     Document Type: Review

References (28)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edn. Arlington: American Psychiatric Association. 2013. http://www.psych.org/practice/dsm/dsm5. Accessed 3 Oct 2013.
2. McClellan J, Kowatch R, Findling R, the Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107-25.
3. National Institute for Health and Clinical Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38. 2006. http://www.nice.org.uk/nicemedia/live/10990/30194/30194.pdf. Accessed 7 Oct 2013.
4. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346-88.
5. Merikangas KR, Nakamura EF, Kessler RC. Epidemiology of mental disorders in children and adolescents. Dialogues Clin Neurosci. 2009;11(1):7-20.
6. European Medicines Agency. Abilify 5 mg tablets: summary of product characteristics. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000471/WC500020170.pdf. Accessed 20 Sept 2013.
7. Dhillon S. Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Drugs. 2012;72(1):133-62.
8. Grunder G, Kungel M, Ebrecht M, et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry. 2006;39(Suppl 1):S21-5.
9. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
10. Tadori Y, Forbes RA, McQuade RD, et al. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol. 2011;668(3):355-65.
11. 11C] raclopride. Neuropsychopharmacology. 2002;27(2):248-59.
12. 1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164(9):1411-7.
13. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44(2):179-87.
14. Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol. 2008;28(4):441-6.
15. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441-51.
16. Findling RL, Correll CU, Nyilas M, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord. 2013;15(2):138-49.
17. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment Report: Abilify (aripiprazole). 2012. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000471/ WC500138620.pdf. Accessed 17 Sep 2013.
18. Mankoski R, Zhao J, Carson WH, et al. Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study. J Child Adolesc Psychopharmacol. 2011;21(4):359-64.
19. Soutullo CA, Escamilla-Canales I, Wozniak J, et al. Pediatric bipolar disorder in Spanish sample: features before and at time of diagnosis. J Affect Disord. 2009;118:39-47.
20. Masi G, Perugi G, Toni C, et al. Attention-deficit hyperactivity disorder: bipolar comorbidity in children and adolescents. Bipolar Disord. 2006;8(4):373-81.
21. Keck PE. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry. 2005;66(Suppl 3):5-11.
22. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9-20.
23. National Institute for Health and Clinical Excellence. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. NICE technology appraisal guidance 292. 2013. http://www.nice.org.uk/ nicemedia/live/14225/64565/64565.pdf. Accessed 9 Oct 2013.
24. Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62:1305-12.
25. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46(6):687-700.
26. Almandil NB, Liu Y, Murrya ML, et al. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Pediatric Drugs. 2013;15:139-50.
27. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotics during first-time use in children and adolescents. JAMA. 2009;302(16):1765-73.
28. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry. 2002;180:227-33.